Sales & Earnings In Brief
This article was originally published in The Tan Sheet
Executive Summary
Sanofi seeks more acquisitions: Sanofi-Aventis continues to "hunt" for bolt-on acquisitions to further diversify its portfolio and feed its pipeline now that it has "properly bedded down and integrated" Chattem, said CEO Chris Viehbacher. He told analysts April 29 that the environment is "quite promising" for acquisitions and Sanofi is "aggressively pursuing external growth opportunities." The Chattem deal significantly boosted Sanofi's consumer health care business, which grew 42.5 percent to €499 million ($661.1 million) in the firm's fiscal 2010 first quarter, according to a same-day release (1"The Tan Sheet" March 15, 2010). Viehbacher lauded Chattem as a keystone in the company's future as a switch platform for the allergy medication Allegra. He noted Sanofi filed the paperwork with FDA for the switch in March; he expects the switch evaluation to take the same amount of time as other new product applications. Prescription sales for Allegra fell 27.1 percent in the quarter due to new competition from generics launched in the U.S. last November. Overall sales for the Paris-based firm grew 5.8 percent, according to the release
You may also be interested in...
Reckitt Extends Children's Mucinex Line In Widening Consumer Strategy
Reckitt Benckiser announces a line extension for its Mucinex franchise as the firm prepares for an earlier-than-expected loss of exclusivity for the decongestant product
Sales & Earnings In Brief
OTCs fill pharma gap for Bayer: Lower sales of Rx pharmaceuticals in the U.S., attributable to generic competition for some drugs, are counterbalanced by the "particularly pleasing growth" of Bayer HealthCare's Consumer Health segment, says Chairman Werner Wenning. During a July 29 call, Wenning noted OTC business grew 6 percent in the firm's fiscal 2010 second quarter, with Bayer Aspirinup 6 percent and Aleve up 14.3 percent. Sales of the One A Day multivitamin line, which expanded in May with the launch of Men's Pro Edge formula, grew 14.8 percent. Wenning attributed the consumer product growth to economic recovery and increased consumption in the U.S. Bayer HealthCare reported overall quarterly sales rose 6.4 percent, adjusted for currency exchange, to 4.31 billion euros ($5.6 billion under July 29 conversion rates). The German chemical and pharmaceutical giant's first-half health care sales gained 3.6 percent to reach $10.6 billion
Reckitt Would Add Durex, Scholl Brands With SSL Acquisition
Reckitt Benckiser moves again to grow its consumer products business, particularly in Asian markets, with an offer to acquire Durex condoms and Scholl foot care products manufacturer SSL International